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Abstract: Gulf War Illness (GWI) is a chronic multi-symptomatic illness that is associated with fatigue,
pain, cognitive deficits, and gastrointestinal disturbances and presents a significant challenge to
treat in clinics. Our previous studies show a role of an altered Gut–Brain axis pathology in disease
development and symptom persistence in GWI. The present study utilizes a mouse model of GWI
to study the role of a labdane diterpenoid andrographolide (AG) to attenuate the Gut–Brain axislinked pathology. Results showed that AG treatment in mice (100 mg/kg) via oral gavage restored
bacteriome alterations, significantly increased probiotic bacteria Akkermansia, Lachnospiraceae, and
Bifidobacterium, the genera that are known to aid in preserving gut and immune health. AG also
corrected an altered virome with significant decreases in virome families Siphoviridae and Myoviridae
known to be associated with gastrointestinal pathology. AG treatment significantly restored tight
junction proteins that correlated well with decreased intestinal proinflammatory mediators IL-1β and
IL-6 release. AG treatment could restore Claudin-5 levels, crucial for maintaining the BBB integrity.
Notably, AG could decrease microglial activation and increase neurotrophic factor BDNF, the key to
neurogenesis. Mechanistically, microglial conditioned medium generated from IL-6 stimulation with
or without AG in a concentration similar to circulating levels found in the GWI mouse model and
co-incubated with neuronal cells in vitro, decreased Tau phosphorylation and neuronal apoptosis.
In conclusion, we show that AG treatment mitigated the Gut–Brain-Axis associated pathology in
GWI and may be considered as a potential therapeutic avenue for the much-needed bench to bedside
strategies in GWI.
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1. Introduction
Gulf War Illness (GWI) is a chronic, multi-symptomatic, and medically unexplained
disorder that affected almost a third of the returning veterans deployed in the Persian
Gulf War of 1990–91 [1,2]. As per the epidemiological study conducted by Steele et al.
on a large population of Kansas Gulf War veterans, reported cases of GWI should enlist
at least three moderate to severe symptoms out of six pre-defined symptom domains
to be qualified as GWI [3]. These pre-defined six domains consist of i. chronic fatigue
problems, ii. somatic pain, iii. neurological or cognitive problems, iv. gastrointestinal (GI)
problems, v. respiratory problems, vi. dermatological issues. The deployed veterans were
directly exposed to numerous toxicants during the wartime, including pesticides such as
permethrin (Per), nerve gas antidote pyridostigmine bromide (PB), chemical agents, e.g.,
sarin gas, mustard gas, depleted uranium, as well as various combustion products from
the burnt oil wells [4,5]. Exposure to these hazardous chemicals combined with wartime
stress resulted in the persistence of the prolonged symptoms among the veterans even after
30 years since the war ended. Understanding and treating the myriad of elusive symptoms
associated with GWI etiology remains a major challenge for both clinicians and scientists.
We were the first group to establish a notable connection between the gut microbiome
and GWI pathology, where we showed that the administration of Gulf War chemicals
(GWC) in a mice model caused an alteration of the gut bacteriome signature, which
in turn led to increased intestinal inflammation, gut leaching, endotoxemia, and release of the damage-associated molecular pattern (DAMP) HMGB1 (High motility group
box 1) [6,7]. Subsequently, we have shown that GWI-associated dysbiosis in mice resulted in a decrease of the probiotic butyrogenic bacteria [7,8], increased Firmicutes abundance over Bacteroidetes in the phylum level [6,7], and a decrease of the probiotic species
Akkermansia muciniphila [9] and these alterations attributed to increased intestinal inflammation, gut leaching [7,8,10,11], enteric glial cell activation [12], hepatic metabolic reprogramming [8,11], neuronal inflammation [6,7,9,10], the systemic release of HMGB1 [7,8],
symptoms all of which fall under GWI pathology domain. We have also shown that
administration of oral butyrate and the nutraceutical Sparstolonin B in mice helped to
restore normal bacteriome patterns and decreased GWI-associated symptoms as described
previously. In addition to bacteriome alteration, we were the first group to report that GWC
treatment in mice changed the gut virome pattern, where we observed an increased abundance of Siphoviridae and Myoviridae along with decreases in Microviridae abundance [10].
This virome dysbiosis correlated with GWI pathological symptoms, and the use of the
anti-viral drug Ribavirin helped to diminish the symptoms [10]. These studies formed
the basis of our microbiome targeted therapy for GWI, as the lack of proper therapeutic
compounds is preventing affected veterans from getting treatment.
Andrographolide (AG) is a well-known bioactive phytoconstituent extracted from the
plant Andrographis paniculata and is highly popular as an alternative medicine in SouthEast Asian countries, e.g., India, China. Structure wise, AG is a labdane diterpenoid,
which exerts numerous pharmacological effects including anti-inflammation [13,14], antioxidative stress [15], anti-cancer [16], hepatoprotection [17,18], anti-fibrosis [19,20], and
neuroprotection [21–23]. Mechanistically, AG is a known inhibitor of the nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB) pathway, which explains its antiinflammatory nature [24]. Besides inhibiting the NF-kB pathway, AG has been shown to
participate in various signaling pathways in various cell types and organ systems [25].
Interestingly, Bera et al. showed that AG can cross the blood–brain barrier [26] and possibly
can enter into the cells via passive diffusion, as any AG-specific receptor has not been
found to date [27]. Considering all the beneficial roles that AG possesses and its multitarget nature, we wanted to observe whether AG administration in GWC treated mice can
restore their altered bacteriome as well as the virome pattern and attenuate GWI-associated
symptoms, including gut inflammation, leaking of the gut, systemic inflammation, and
various neuropathology. We also wanted to determine the role of AG in diminishing
Interleukin-6 (IL-6) treated microglial activation and resulting neuronal apoptosis in vitro.
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2. Materials and Methods
2.1. Materials
Permethrin (PER), pyridostigmine bromide (PB) were obtained from Sigma-Aldrich
(St. Louis, MO, USA), whereas andrographolide (AG) was bought from Cayman Chemical
(Ann Arbor, MI, USA). Primary antibodies, including anti-Occludin, anti-Claudin-2, and
anti-transmembrane protein 119 (TMEM119), anti-phosphorylated Tau (p-Tau) were purchased from Abcam (Cambridge, MA, USA). Anti-Flotillin 1, anti-interleukin-1β (IL-1β),
anti-interleukin-6 (IL-6), anti-brain-derived neurotrophic factor (BDNF), and anti-Cluster
of Differentiation 40 (CD40) primary antibodies were bought from Santacruz Biotechnology (Dallas, TX, USA). Anti-myeloid differentiation primary response protein (MyD88),
anti-Toll-like receptor 4 (TLR4) primary antibodies were purchased from Abclonal Technology (Woburn, MA, USA), whereas Anti-NF-κB p65, anti-phospho NF-κB p65, anti-Tau,
anti-Bcl-2-associated X protein (BAX), anti-Cleaved Caspase 8, anti-Caspase 8, anti-Cleaved
Caspase 3, Caspase 3 antibodies were purchased from Cell Signaling Technology (Danvers,
MA, USA). Anti-β-actin and anti-B-cell lymphoma 2 (Bcl-2) antibodies were purchased
from Proteintech (Rosemont, IL, USA). Species-specific biotinylated conjugated secondary
antibody and Streptavidin-horse radish peroxidase (HRP) (Vectastain Elite ABC kit) were
obtained from Vector laboratories (Burlingame, CA, USA). Fluorescence conjugated Alexa
Fluor secondary antibodies, as well as ProLong Diamond antifade mounting media with
40 ,6-diamidino-2-phenylindole (DAPI), were bought from Thermo Fisher Scientific (Rockford, IL, USA). Recombinant mouse IL-6 was purchased from Sino Biological (Wayne, PA,
USA). All the necessary chemicals used in this study were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Murine small intestine and brain tissues were processed at AML
Laboratories (Jacksonville, FL, USA) and Instrument Resources Facility, University of South
Carolina School of Medicine (Columbia, SC, USA) for paraffin-embedding and sectioning
into slides. Bacteriome analysis was performed by Cosmos ID (Rockville, MD, USA).
2.2. Animals
Adult (10 weeks old), wild-type, pathogen-free, male C57BL/6J mice were purchased
from Jackson Laboratories (Bar Harbour, ME, USA). Mice experiments were conducted
maintaining the National Institutes of Health (NIH) guideline for human care and use
of laboratory animals and local Institutional Animal Care and Use Committee (IACUC)
standards (Animal Use Protocol reference number: 101345; Protocol Number: 2419-101345072318; approval date: 23 July 2020). The animal handling procedures were approved by
the University of South Carolina (Columbia, SC, USA). Upon arrival, all mice were housed
in a temperature (22–24 ◦ C) and humidity-controlled animal room and had ad libitum
access to chow diet and water with a 12-h light/12-h dark cycle. Mice were sacrificed after
completion of the dosage regimen. Immediately after anesthetization, blood was collected
from mice using the cardiac puncture method, and serum was extracted from it. All serum
samples were preserved at −80 ◦ C until further analysis was performed. Organs, including
the distal parts of the small intestine, were collected and fixed in 10% neutral buffered
formaldehyde (Sigma-Aldrich, St. Louis, MO, USA), whereas the frontal cortexes were
collected and fixed in Bouin’s solution (Sigma-Aldrich, St. Louis, MO, USA). Fecal pellets
were collected from the colon and preserved at −80 ◦ C for microbiome analysis.
2.3. Mouse Model of Gulf War Illness
GW chemicals (PER and PB) were used to expose the mice following well-established
acute rodent models of Gulf War illness with some modifications [7,9,11]. All mice were
randomly divided into 4 groups after 1 week of acclimatization. The 1st group was
CONTROL (n = 11), and mice were administered with vehicle (0.6% DMSO diluted in PBS)
only. The 2nd group was GWT (n = 11), where mice were administered with the mixture of
GW chemicals PER (200 mg/kg body weight, dissolved in DMSO and diluted in PBS; the
final concentration of DMSO was 0.6%) and PB (2 mg/kg body weight; diluted in PBS) by
oral gavage. The 3rd group (GWT+AG) (n = 6) was treated with both GW chemicals and
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AG. Mice were dosed with GW chemicals first, followed by AG (100 mg/kg body weight)
by oral gavage. Finally, the 4th group of mice received only andrographolide (AG) (n = 6)
by oral gavage, similar to the 3rd group. GW chemicals and AG were administered to the
mice every alternate day for a 1-week time period. Each mouse, according to their assigned
group, received 100 µL of the vehicle or GW chemicals and/or AG.
2.4. Cell Culture
2.4.1. Mouse Microglial Cell Culture and Treatment
Immortalized mouse microglial SIM-A9 cell line (ATCC® CRL-3265™) was purchased
from ATCC (Manassas, VA, USA). SIM-A9 cells were maintained using a complete growth
medium consisting of Dulbecco’s Modified Eagle Medium: F12 (DMEM: F-12 Medium)
(ATCC® 30-2006™) supplemented with 10% fetal bovine serum (FBS), 5% heat-inactivated
horse serum, 100 U/mL Penicillin, 100 µg/mL Streptomycin (Gibco, NY, USA) and incubated in a humidified 5% CO2 incubator at 37 ◦ C. Prior to cell passage, SIM-A9 cells
were washed with Dulbecco’s phosphate-buffered saline (DPBS) and then detached using
a mixture of 1mM EDTA, 1 mM EGTA, and 1 mg/mL glucose in DPBS.
Approximately 0.3 × 106 cells/well were seeded onto a 6 well tissue culture plate.
Serum starvation was performed using DMEM: F-12 Medium containing 1% FBS only for
18 h when the cells attained almost 70% confluency. Following that, cells were treated with
vehicle control (0.05% DMSO) only (CONTROL), mouse recombinant IL-6 (64 pg/mL) only
(IL-6), 50 µM andrographolide only (AG50), and a combination of both IL-6 (64 pg/mL)
and 50 µM andrographolide (IL-6+AG50) for 24 h. IL-6 concentration used for this cell
treatment was determined by our in vivo IL-6 serum ELISA result. Upon completion of
treatment, supernatant from each experimental group was collected, centrifuged, and
stored at −80 ◦ C. These supernatants containing the secretome of the treated SIM-A9
cells were used as “Microglial-conditioned Medium” (MCM) to treat the Neuro-2a cells
for the next part of our in vitro experiments. In addition, ELISA was performed using
these cell supernatants to quantify the level of TNFα secretion by SIM-A9 cells for each
experimental group.
2.4.2. Mouse Neuronal Cell Culture and Treatment
Mouse neuroblastoma cell line Neuro-2a (N2a) (ATCC® CCL-131™) was obtained
from ATCC (Manassas, VA, USA). These N2a cells were maintained on Eagle’s Minimum
Essential Medium (EMEM) (ATCC® 30-2003™) supplemented with 10% FBS, 100 U/mL
Penicillin, 100 µg/mL Streptomycin (Gibco, NY, USA) and incubated in a humidified 5%
CO2 incubator at 37 ◦ C.
Cells were plated on a 6 well plate with a seeding density of 0.3 × 106 cells/well and
were grown till the cells reached almost 70% confluency. Then, the N2a cells were serumstarved for 18 h using EMEM supplemented with 1% FBS. Following serum starvation,
the cells were treated with a combination of MCM obtained from each SIM-A9 microglia
experimental group and normal N2a growth medium for 24 h. The groups designed for this
experiment were unchanged from the last SIM-A9 cells experiment (CONTROL, IL-6, AG50,
and IL-6+AG50). Post-treatment, cell supernatants were collected, stored at −80 ◦ C, and
proteins from each group were extracted using 1× RIPA lysis buffer containing protease
and phosphatase inhibitors. The concentration of the extracted protein samples from each
group was estimated using the BCA assay kit (Thermo Fisher Scientific, Rockford, IL, USA),
and the Western Blot experiment was performed using these extracted protein samples.
2.5. Microbiome Analysis
2.5.1. Bacteriome Analysis
Bacteriome analysis was performed by CosmosID (Rockville, MD, USA) using the fecal
pellets obtained from individual mouse samples after euthanization. Briefly, DNA isolation
was performed from these fecal pellets using the ZymoBIOMICS Miniprep kit following the
manufacturer’s protocol. After that, sequencing was conducted with a 2-step polymerase
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chain reaction (PCR) targeting the V3V4 (341 nt–805 nt) region of the bacterial 16S ribosomal
RNA (rRNA) gene. At first, a 16S-optimized primer was used in PCR to amplify the V3-V4
regions of the 16S ribosomal DNA (rDNA). Then, these PCR amplicons were used as
templates with adapters containing 8 bp index for the 2nd step to prepare Illumina dualindex libraries and further processed for sequencing purposes. These dual-index library
amplicon products were purified by using Ampure beads (Beckman Coulter, Brea, CA,
USA). Quantification of the dual-index library was performed by using Qubit dsDNA HS
assay (Thermo Fisher), followed by qualification on a 2100 Bioanalyzer instrument (Agilent,
Santa Clara, CA, USA) where the distribution with a peak in the expected range was
scrutinized. Final quantification was conducted by performing quantitative PCR (qPCR),
followed by loading onto MiSeq (Illumina, San Diego, CA, USA) sequencer for PE250
(v2 chemistry). Sequences obtained for each sample were finally run on the 16S pipeline
of the CosmosID GENIUS software, and results were analyzed. This whole bacteriome
analysis process for this study was performed according to standard protocol optimized by
the vendor.
2.5.2. Virus-Like Particle (VLP) Enrichment and Total Nucleic Acid Extraction
Mouse fecal specimens (approximately 58 mg) were diluted in 1200 µL of SM Buffer (GBiosciences, Maryland Heights, MO, USA), vortexed at 3000 rpm for 5 min, then centrifuged
at 7000× rcf for 10 min. The supernatant was filtered through a 0.45 µm membrane
(Celltreat, Pepperell, MA, USA). The stool filtrates were treated with lysozyme (Sigma) and
baseline-ZERO DNase (Lucigen, Middleton, WI, USA) to degrade unencapsulated DNA.
DNase treatment was inactivated with EDTA (5 mM final concentration). Total nucleic acid
was extracted using the eMAG instrument (bioMérieux, Marcy-l’Étoile, France). Negative
controls were included in the same extraction process to assess contamination. VLP DNA
was amplified with GenomiPhi V2 (GE Healthcare, Chicago, IL, USA) before Illumina
library construction. The negative controls were spiked with Enterobacteria phage λ DNA
to assess cross-contamination and amplification. Samples and negative controls were
pooled for sequencing in an Illumina NovaSeq 6000 2 × 150 bp sequencing run. A total of
549,782,556 sequencing reads were generated, resulting in an average of 14,858,988 reads
per sample.
Reads with a minimum length of 75 and an average quality score above 20 were
retained for further analysis using bbduk. After quality control, 352,385,124 reads remained,
resulting in an average of 9,523,922 reads per sample. Viral contigs were assembled using
metaSPAdes version 3.14.0 from QC reads (28,298,430). Contigs were then filtered to
a minimum length of 500 base pairs using CD-HIT and de-duplicated to a minimum
identity of 99% [28,29]. Contigs mapping to the host mouse genome were discarded.
Bacteriophage contigs were identified by merging VirSorter called contigs and contigs
identified by MegaBLAST as being from bacteriophage families [30]. Eukaryotic contigs
were identified by querying contigs against a viral NR database using blastx. Bacteriophage
and eukaryotic contigs were then merged, and taxonomy was retrieved using a taxonomizr
(Supplementary Table S1). BWA-MEM was used to get the number of reads associated
with each contig by mapping the QC reads against the contigs generated. Read counts
were then normalized by reads per kilobase hundred thousand in an RPKM fashion.
Contaminants were removed using decontam using the prevalence method with a threshold
of 0.3 [31]. Decontam identified and removed 14 contaminants leaving an average of 99.98%
of viral counts (Supplementary Figure S2). Richness, Shannon diversity, and beta diversity
measurements were calculated with the QIIME2 package [32]. Discriminant analysis was
performed using LEfSe to determine features between treatment groups and MaaAsLin2 for
discriminant features by cytokine and protein levels [33]. Data visualization and statistical
tests were conducted using Graphpad Prism. All virome comparisons were conducted
using the Mann–Whitney U test.
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2.5.3. Availability of Data and Materials
Sequence data are in the processing of being deposited to the NCBI Sequence Read
Archive under BioProject (accession number PRJNA731934).
2.6. Laboratory Methods
2.6.1. Immunohistochemistry
Deparaffinization procedure of paraffin-embedded small intestine and brain tissue
sections was performed following standard laboratory procedure. Briefly, 5 µm-thick tissues were immersed successively in 100% xylene, 1:1 solution of xylene and ethanol, 100%
ethanol, 95% ethanol, 70% ethanol, 50% ethanol, deionized water for 3 min each. Following
deparaffinization, antigen epitope retrieval was conducted by using the Epitope retrieval
solution and steamer (IHC-World, Woodstock, MD, USA). Endogenous peroxidase activity
was blocked by using 3% H2 O2 solution for 20 min, followed by serum blocking (5% goat
serum) for 1 h. After serum blocking, primary antibodies for IL-1β, IL-6, and BDNF were
diluted (1:300) in blocking buffer and applied to the tissue sections. All sections were kept
at 4 ◦ C for overnight incubation in a humidified chamber. After overnight incubation, the
tissue sections were washed with 1X PBS-T (PBS+ 0.05% Tween 20) 3 times. Biotinylated
secondary antibodies (species-specific) were probed at 1:250 dilution, followed by incubation with streptavidin-conjugated with horseradish peroxidase at 1:200 dilution. Finally, the
chromogenic substrate solution of 3,3 diaminobenzidine (DAB) (Abcam; Cambridge, MA,
USA) was applied to the sections, and counterstaining was performed by using Mayer’s
hematoxylin (Sigma-Aldrich, St. Louis, MO, USA). Mounting of all tissue sections was
conducted by using Simpo mount (GBI Laboratories, Mukilteo, WA, USA). Reactivity of the
applied antibodies in the sections was observed under 10× and 20× objectives and images
were captured using an Olympus BX43 microscope (Olympus, America). Morphometric
data analyses were performed by CellSens Software from Olympus America (Center Valley,
PA, USA).
2.6.2. Immunofluorescence Staining
Deparaffinization and epitope retrieval procedures of the paraffin-embedded small
intestine and brain tissue sections were performed similarly as mentioned above. After
completion of the epitope retrieval process, the tissue sections were permeabilized by
using PBS-T (PBS+ 0.1% Triton X-100) solution for 1 h, followed by blocking with 5% goat
serum for 1 h. After that, tissue sections were incubated with primary antibodies of antiOccludin, anti-Claudin-2, anti-TLR4, anti-Flotillin1, anti-Claudin-5, anti-CD31, anti-CD40,
and anti-TMEM119 (at 1:300 dilution) and kept overnight at 4 ◦ C in a humidified chamber.
Then, species-specific anti-IgG secondary antibodies conjugated with Alexa Fluor 488 or
633 from Invitrogen (Rockford, IL, USA) were used at 1:250 dilutions. Finally, mounting
was performed by using ProLong Gold antifade reagent with DAPI (Life Technologies,
Carlsbad, CA, USA). Images were taken under 10×, 40×, and 60× magnification with
an Olympus BX63 microscope. Morphometric data analyses were performed by CellSens
Software from Olympus America (Center Valley, PA, USA).
2.6.3. Western Blot
Proteins were extracted from the small intestine tissue samples and cells using 1× RIPA
lysis buffer containing protease and phosphatase inhibitors. Estimation of the extracted
tissue and cellular proteins was performed by using the BCA assay kit (Thermo Fisher
Scientific, Rockford, IL, USA). Approximately 30 µg of extracted proteins from each sample
were added to a mixture containing 1× NuPAGE™ LDS Sample Buffer (Thermo Fisher
Scientific, Rockford, IL, USA) and 10% β-mercaptoethanol, followed by boiling for 5 min.
Then, the protein samples were subjected to standard SDS-PAGE using Novex 4–12%
bis-tris gradient gel. Membrane transfer of separated protein bands on a nitrocellulose
membrane was performed by using the Trans-Blot Turbo transfer system (Bio-rad, Hercules,
CA, USA), and the membrane was blocked with 3% bovine serum albumin (BSA) for 1 h.
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Anti-TLR4, anti-TLR7, anti-MyD88, anti-β-actin, anti-NF-κB p65, anti-phospho NF-κB
p65, anti-phospho-Tau, anti-total-Tau, anti-BAX, anti-Bcl-2, anti-Cleaved Caspase 8, antiCaspase 8, anti-Cleaved Caspase 3, anti-Caspase 3 primary antibodies were incubated
using 1:1000 dilution overnight at 4 ◦ C. Compatible horseradish peroxidase-conjugated
species-specific secondary antibodies were used to probe the primary antibody. Pierce ECL
Western blotting substrate (Thermo Fisher Scientific, Waltham, MA, USA) was used for blot
development. Finally, the blots were captured by G: Box Chemi XX6, and densitometry
analysis was performed using Image J software.
2.6.4. Enzyme-Linked Immunosorbent Assay (ELISA)
Serum IL-1β and IL-6 levels were estimated with serum samples obtained from
CONTROL, GWT, GWT + AG, and AG mice groups using the ELISA kit from ProteinTech
(Rosemont, IL, USA) following the manufacturer’s protocol. In addition, TNFα ELISA
was performed as per the manufacture’s instruction (ProteinTech, Rosemont, IL, USA) to
measure the secreted level of TNFα using the mouse microglial SIM-A9 cell supernatants.
2.7. Statistical Analyses
All statistical analyses were performed using GraphPad Prism software (San Diego,
CA, USA). Unpaired t-test (two-tailed tests with equal variance) and one-way analysis
of variance (ANOVA) were carried out for determining the difference between multiple
groups, followed by Bonferroni–Dunn post-hoc corrections analysis for all intergroup
comparisons. For all analyses, p ≤ 0.05 was considered statistically significant, and data
were presented as the mean ± SEM.
3. Results
3.1. Andrographolide Treatment Restores GW Chemical-Associated Bacteriome Alteration in Mice
Previous studies from our group have consistently shown that GW chemical administration in mice causes a significant alteration in the normal gut microflora [7–10,12]. In this
study, we wanted to observe whether AG administration can directly affect the dysbiosis of
the bacteriome, caused by GW chemicals PB and PER. Using fecal pellets obtained from the
mice model of GWI, next-generation sequencing was carried out for detailed microbiome
analysis. Consistent with our previous findings, an increase in the relative abundance of
the phylum Bacteroidetes was observed parallelly to a decreased relative abundance of
Firmicutes in the GWT group (Figure 1A). Conversely, AG treatment significantly increased
Firmicutes abundance and decreased Bacteroidetes abundance in the GWT+AG group
when compared to the GWT group (Figure 1A). At the genus level, we observed that AG
enhanced the abundance of many bacteria, which were beneficial for the host. The relative
abundance of the individual genus, calculated between different treatment groups, was
depicted as a percentage value. Results showed that Lachnospiraceae_u_g and Akkermansia,
which impart several advantageous effects, including anti-inflammatory properties and
mucin layer protection, were increased in the GWT+AG group compared to both Control and GWT groups, respectively (Figure 1B) [34,35]. Bifidobacterium is a butyrogenic
bacteria that belong to the phylum Firmicutes and is a known probiotic [36]. It was observed that AG treatment via oral gavage administration aided in the relative abundance of
Bifidobacterium in the intestinal microenvironment of GWT+AG mice, which was otherwise
absent in both the Control and GWT groups (Figure 1B). Members of the Staphylococcus
genus primarily consisted of many opportunistic pathogens [37]. Our analysis showed
an increased relative abundance of Staphylococcus genus in the GWT group compared to
the Control group. Surprisingly, AG treatment led to a total depletion of this genus in
the GWT+AG group. However, the relative abundance of Dorea was not decreased in the
GWT+AG group when compared to the GWT group. In addition, the relative abundance of
Lactobacillus was not found to be significantly increased in the GWT+AG group, compared
to both Control and GWT groups.
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3.2. Virome Alteration Associated with Andrographolide Administration in a Mouse Model of GWI
Previous findings have shown that GWI immune responses were associated with viral
dysbiosis [10]. Therefore, we performed viral sequencing of the mice fecal pellets to assess
changes in the composition of the virome between treatment groups. Major viral families
identified included Microviridae, Siphoviridae, and Myoviridae across all treatment groups
(Figure 2A). While there were no significant differences in Microviridae counts between
treatment groups, AG treatment resulted in significantly decreased Siphoviridae, Myoviridae,
and Inoviridae RPK counts (Figure 2B). AG treatment alone or in combination resulted in
significantly decreased Myoviridae and Inoviridae counts. To assess the overall composition
changes between treatment groups, we measured contig richness and Shannon diversity. The richness and Shannon diversity were significantly decreased in AG-treated mice
compared to GWT mice (Figure 2C,D). Principle coordinate analysis using unweighted
Bray–Curtis distances was used to compare compositional relationships between individual samples (Figure 2E). The virome of Control and GWT mice overlapped (PERMANOVA
p = 0.088), while the GWT+AG and AG mice clustered distinctly from one another (PERMANOVA p = 0.002; p = 0.001). We next sought to identify viral features discriminant
between treatment groups. We performed LEfSe analysis and identified significant overlap
in contigs associated with Control and GWT groups with fewer overlapping features with
the AG-treated groups (Figure 2F). This indicated that AG treatment specifically affects
certain components of the virome (Supplementary Table S2). These results also indicated
that AG treatment significantly alters the diversity and composition of the gut virome
independent of the healthy no-exposed virome.
3.3. AG Treatment Improves the Integrity of Intestinal Tight Junction Proteins and Decreases GW
Chemical-Induced Gut Leaching
Tight junction (TJ) proteins are responsible for maintaining epithelial barrier integrity,
which in turn is essential for regulating nutrient absorption, transport of selective content
from the lumen, and blockage of pathogen entry [38,39]. In our previous studies, we
showed that GW chemical exposure led to an altered expression of TJ proteins, where
Claudin-2 expression was increased with a simultaneous decrease in Occludin expression,
leading to gut leaching [7,11]. In this study, we wanted to show whether AG was able
to revert the altered expression of TJ proteins in GW chemical-exposed mice. Results
showed that Occludin expression significantly decreased (Figure 3A,C, *** p < 0.001),
and Claudin-2 expression were significantly increased (Figure 3B,D, *** p < 0.001) in the
GWT group when compared to the Control group consistent with our previous studies.
However, Occludin expression was significantly increased (Figure 3A,C, *** p < 0.001)
whereas Claudin-2 expression decreased significantly (Figure 3B,D, *** p < 0.001) in the
mice group co-exposed to both GW chemicals and AG, compared to the GWT group alone
as detected by immunofluorescence microscopy. No significant change in Occludin or
Claudin-2 protein expression was observed between the vehicle-treated control, and the
only AG-treated mice groups (Figure 3A–D, NS = non-significant). Principle coordinate
analysis of the virome showed a significant difference in the beta diversity of mice with
high Occludin levels (PERMANOVA p = 0.041) but did not show a significant relationship
with Claudin-2 levels (PERMANOVA p = 0.188) (Supplementary Figure S1). The virome
also showed specific trends when analyzed by immune marker levels. MaAsLin2 was used
to determine associations between immune marker levels and viral counts. Results showed
a negative correlation between Occludin levels and significant contigs and a positive trend
between Claudin-2 levels and viral contigs (Supplementary Table S3). These results confirm
that AG played a direct role in restoring gut barrier integrity of GW chemical-treated mice
partly via its role in restoring the virome and its direct effect on the expression of TJ proteins.
A decontam analysis of virome samples are included in Supplementary Figure S2.
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3.4. AG Attenuated Toll-Like Receptor-Mediated Downstream Proinflammatory NF-κB Signaling
Pathway Following Altered Gut Bacteriome-Virome
A combined effect of the “leaky gut” phenotype and gut dysbiosis resulted due
to GW chemical exposure can subsequently trigger the host’s TLR-mediated innate immune system [7,8,10]. Dual-labeling was performed on the intestine tissue sections to
observe TLR4-Flotiilin1 co-localization events, which is a signature of TLR4 activation.
Results showed a significantly increased co-localization of TLR4 and Flotillin1 (Figure 4A,B;
*** p < 0.001) represented by yellow dots and encircled in white) in the epithelia of the small
intestine compared to the Control group. However, this co-localization was significantly
decreased in the GWT+AG group when compared to the GWT group alone (Figure 4A,B;
*** p < 0.001). No significant difference of TLR4-Flotillin1 co-localization was observed
between the Control, and only AG-treated mice groups (Figure 4A,B, NS = non-significant).
This result indicated enhanced TLR4 trafficking to the lipid rafts of the intestinal epithelial region due to GW chemical-driven microbial dysbiosis and a leaky gut. We further
confirmed our results by studying TLR4 protein expression level via Western blot analysis
of small intestinal tissue lysates. Results showed an increased expression of TLR4 in the
GWT group compared to the control group (Figure 4C,D, ** p < 0.01). Further, TLR4
total protein expression was decreased significantly in the GWT+AG group compared
to the GWT group (Figure 4C,D, * p < 0.05). A significant difference in TLR4 expression
was not found when the vehicle-treated Control group and only the AG-treated group
were compared (Figure 4C,D, NS = non-significant). These results, when combined with
TLR4-Flotillin1 co-localization events, confirmed activation and enhanced expression of
TLR4 in the GW exposed mice and its modulation by AG. Next, we wanted to study
whether AG-induced modulation of the virome in the GW chemical-treated mice and its
downstream signaling could be mediated by the deactivation of TLRs known for virome
sensing in the intestinal microenvironment. Western blot analysis showed that TLR7 protein expression was increased markedly in the GWT group when compared to Control
while AG administration (GWT+AG group) (Figure 4C,D; *** p < 0.001) significantly decreased its expression. MyD88 is a known adaptor molecule essential for both TLR4 and
TLR7 mediated downstream proinflammatory signaling pathways [40,41]. We observed
that the MyD88 protein expression level was significantly enhanced in the GWT group
compared to Control and AG administration significantly decreased MyD88 protein levels
(Figure 4C,D; *** p < 0.001) and was able to restore the levels of these proteins to the control
level (Figure 4C,D; * p < 0.05), (Figure 4C,D; NS = non-significant). Further, we wanted to
investigate whether TLR-mediated downstream NF-κB signaling was activated. Indeed,
Western blot analysis showed phosphor-NF-κB p65 expression (normalized against totalNF-κBp65) was markedly enhanced in the small intestine of the GWT group compared to
the Control group (Figure 4C,E; *** p < 0.001). AG, being an NF-κB inhibitor, decreased
phosphor-NF-κB p65 expression in the GWT and AG co-exposed mice compared to the
GWT mice group (Figure 4C,E; *** p < 0.001).
3.5. AG Treatment Diminishes Both Intestinal and Systemic Inflammation in a Mouse Model
of GWI
Activation of TLR4/TLR7-MyD88-NF-κB signaling triggers the production of proinflammatory cytokines (IL-1β, IL-6), which are responsible for localized inflammation [42].
Using immunohistochemistry, we observed that immunoreactivity (observed as brown precipitation and marked inside black circles) of both IL-1β and IL-6 was markedly increased
in the villi region of the small intestine of the GW chemical exposed group compared to
the Control group (Figure 5A–D; *** p < 0.001). AG administration significantly lowered
both IL-1β and IL-6 immunoreactivity in the intestines of the GWT+AG group compared
to the GWT group (Figure 5A–D; *** p < 0.001). Notably, IL-6 expression was found to be
significantly decreased in the only AG-treated group (Figure 5A–D; *** p < 0.001) compared
to the Control group, but no significant difference was observed in the case of IL-1β expression (Figure 5A–D; NS = non-significant). We performed ELISA to check the serum level
of both IL-1β and IL-6 cytokines. Results showed a significant 10-fold increase in IL-1β
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concentration and a 4-fold increase in IL-6 concentration in the serum obtained from GW
chemical exposed groups compared to that of the Control group (Figure 5E,F; *** p < 0.001).
The mice group co-exposed with both GW chemicals and AG had lower serum IL-1β
and IL-6 levels compared to the GWT group (Figure 5E,F; *** p < 0.001). Interestingly,
serum IL-1β concentration in the only AG-treated group was markedly lowered compared
to the vehicle-treated Control group (Figure 5E: *** p < 0.001), but serum IL-6 level was
found to be significantly increased in the only AG group than the Control group (Figure 5F;
* p < 0.05). Principal coordinate analysis was employed to understand the relationship
between IL-6 concentration and virome composition, with no significant difference being
found between IL-6 concentrations (PERMANOVA p = 0.168) (Supplementary Figure S1
Mendeley reference link provided). When MaAsLin2 was used to determine associations
between IL-6 concentrations and viral contig counts, we found a positive trend between
the two (Supplementary Table S3, Mendeley reference link provided). This suggested
that AG not only restored a healthy virome but also attenuated the systemic release of
proinflammatory mediators, an anticipated cause for systemic chronicity of inflammation
found in GWI.
3.6. AG Reverses GWI-Associated Altered Expression of Blood–Brain Barrier (BBB) Claudin-5
Protein and Microglial Activation
Neurological disturbances resulted from various chemical exposure during warfare
are one of the most commonly observed symptoms in GWI pathology [43,44]. The optimal
functioning of BBB prevents the invasion of pathogens and toxins from the bloodstream to
the brain. BBB selectively allows the entry of essential ions and molecules essential for the
homeostatic condition of the Central nervous system [45,46]. We have shown previously
that GW chemical treatment in mice was responsible for the loss of BBB integrity [9]. Consistent with our previous findings, we observed a significantly decreased co-localization
of Claudin-5 (TJ Protein marker of BBB) and CD31 (brain endothelial cell marker) in the
GWT group compared to the vehicle-treated Control group (Figure 6A,B; *** p < 0.001).
However, AG treatment in GW chemical exposed mice significantly increased Claudin-5
and CD31 co-localization events (represented by yellow) in the GWT+AG group compared
to the GWT group alone (Figure 6A,B; *** p < 0.001), referring to attenuation of BBB integrity loss. Analysis of the effects of Claudin-5 and CD31 concentrations on the virome
composition yielded no significant difference in beta diversity over different concentrations
(Supplementary Figure S1, Mendeley_Reference link provided). This is further supported
by MaAsLin2 analysis finding no distinct correlation between Claudin-5 and CD31 levels
and viral contig counts (Supplementary Table S3, Mendeley reference link provided).
Systemic inflammation and dysfunctional BBB often result in the activation of Microglia, resident macrophages of the brain [47,48]. In our present study, microglial activation was observed in the mouse brain by performing dual-labeling of TMEM119
(microglia-specific activation marker) and CD40 (microglial cell surface marker). Significantly increased co-localization of TMEM119-CD40 (marked by yellow and encircled in
white) was observed in the GWT group compared to the Control group (Figure 7A,B;
*** p < 0.001). Conversely, TMEM119-CD40 co-localization was found to be significantly
decreased in the AG and GW chemical co-exposed group compared to the GWT group
alone (Figure 7A,B; *** p < 0.001), suggesting AG treatment had a direct effect in attenuating
the active state of microglia.
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3.7. AG Attenuates Neuroinflammation and Enhanced BDNF Expression in a Mouse Model
of GWI
GW chemical-induced microglial activation triggers heightened neuroinflammation,
a symptom that is strongly associated with GWI pathophysiology [49]. Immunohistochemistry results showed an increased expression of both proinflammatory cytokines
IL-1β and IL-6 in the pre-frontal cortex area of the GWT mice group compared to the
Control group (Figure 8A–D; *** p < 0.001). Neuroinflammation was observed to be significantly decreased in the brain sections of GWT+AG mice compared to GW chemical
exposed mice (Figure 8A–D; *** p < 0.001), indicating the anti-inflammatory role of AG
in the brain tissue. Furthermore, no significant expression of both IL-1β and IL-6 proinflammatory cytokines was observed between the Control group and only AG-treated
group (Figure 8A–D; NS = non-significant), suggesting AG restored the normal levels of
the cytokines mentioned above.
Microglial activation, together with exacerbated neuroinflammation leads to decreased
production of BDNF, a protein that has a prominent role in synaptic plasticity and neuronal
regeneration [50]. As observed by immunohistochemistry results, BDNF protein expression
was markedly decreased in the frontal cortex area of GW chemical exposed mice compared to the Control mice, but the expression was significantly enhanced in the GWT+AG
group (Figure 9A,B; *** p < 0.001). Significantly enough, BDNF expression was not significantly different between the Control group and only AG-treated group (Figure 9A,B;
NS = non-significant), suggesting AG could restore the normal levels of BDNF. These
results explicitly indicated the anti-inflammatory effects of AG in GWI-linked neuroinflammation and restoration of BDNF level by AG administration in GWI murine pathology.
3.8. AG Lessens TNFα Production from Reactive Mouse Microglial Cells, Concomitantly Protects
Mouse Neuronal Cells from Extrinsic Apoptosis and Tau Hyperphosphorylation
Microglia, the resident macrophages of the central nervous system, turn into an active
state when they encounter various external stimuli, which include cytokines, DAMPs,
PAMPs, ROS, and neurotoxins [51]. Although activated microglia are responsible for
mitigating external danger to the CNS, hyperreactive microglia contribute to various
neuropathological conditions, including GWI [49]. In our study, we observed the systemic
rise of the proinflammatory cytokine IL-6, a pivotal mediator of microglial activation, as
well as microglial activation itself in vivo in the GWT group, both of which were decreased
by AG treatment. This led us to hypothesize that perhaps, this IL-6 hypercytokinemia-led
microglial activation may result in the release of TNFα, which in turn may act as an initiator
of the extrinsic apoptotic pathway and tau hyperphosphorylation in neuronal cells. To
prove our hypothesis, immortal mouse microglial SIM-A9 cells were treated with vehicle
(CONTROL) only, IL-6 (IL-6) only, 50 µM AG (AG50) only, and a combination of both
IL-6 and 50 µM AG (IL-6+AG50). IL-6 concentration (64 pg/mL) used for the in vitro
experiment was kept the same as the in vivo ELISA result obtained for the GWT group.
Indeed, Our ELISA result showed that TNFα secretion by the SIM-A9 cells was significantly
increased in the only IL-6 stimulated group (IL-6) compared to both CONTROL and IL6+AG50 groups, respectively (Figure 10A; *** p < 0.001). As expected, no TNFα was
detected in the CONTROL group (Figure 10A: ND = Not detected).
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cantly increased in the only IL-6 stimulated group (IL-6) compared to both CONTROL
and IL-6+AG50 groups, respectively (Figure 10A; *** p < 0.001). As expected, no TNFα was
detected in the CONTROL group (Figure 10A: ND = Not detected).
Next, we used microglia conditioned medium (MCM) obtained from SIM-A9 cells to
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reactive microgliosis as well as the neuroprotective role of AG from extrinsic
24 of 31 apoptosis and
GWI-associated Tau hyperphosphorylation in neurons.
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Neuro-2a cells were treated with MCM collected from SIM-A9 cells, which were treated previously with vehicle only
(CONTROL), IL-6 only (IL-6), a combination of IL-6 and AG 50 µM (IL-6+AG50), and AG 50 µM only (AG50). (B) Western
blot images of p-Tau, t-Tau, BAX, Bcl-2, Cl-Caspase 8, Caspase 8, Cl-Caspase 3, Caspase 3 protein expression level obtained
from Neuro-2a cell lysates. Lanes 1–4 represent CONTROL, IL-6, IL-6+AG50, and AG50 groups, respectively. Densitometry
analyses of (C) phospho-Tau immunoblot normalized against total-Tau, (D) BAX immunoblot normalized against Bcl-2,
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4. Discussion
Gulf War Illness is a chronic multisymptomatic illness often characterized by a myriad of symptoms ranging from chronic fatigue, pain, gastrointestinal disturbances, and
cognitive deficits [52]. Our present study shows profound broad-spectrum probiotic, antiinflammatory, and neurotrophic effects of andrographolide (AG) in a mouse model of
GWI. GWI is presented in the clinics, but a distinct management plan for its treatment
remains elusive. Several preclinical studies have shown effective treatment modalities by
using small molecule intermediates that target the gut microbiome, systemic inflammation,
and/or anti-neuroinflammatory domains [53,54]. A recent spurt in trials of probiotics in
attenuating the GWI symptoms has shown promise after our group established the role of
the microbiome in blood–brain barrier dysfunction and neuroinflammation in the rodent
models of GWI [7,9,10]. We report a novel role of the diterpenoid lactone AG in exerting a
broad-spectrum effect on the gut bacteriome and virome, gastrointestinal inflammation,
BBB dysfunction, microglial activation, and loss of neuronal regeneration via BDNF.
We have shown previously that an altered microbiome in the host gut primarily
because of the exposure to GW chemicals leads to a leaky gut, release of damage-associated
molecular patterns, systemic increase in the proinflammatory cytokines such as IL-1β,
and IL-6 [6]. We also showed that microbiome and virome alterations are strongly linked
to BBB dysfunction and neuroinflammation thus ascribing a distinct role of the Gut–
Brain axis in the pathology [10]. Thus, to tackle such broad pathological consequences
arising from a pathway that connects multiple organ systems need a broad-spectrum
small molecule that would tackle the Gut–Brain-Axis efficiently. Our results showed
that AG administration to mice significantly increased probiotic bacterial species such as
Lachnospiraceae and Akkermansia. Interestingly, both of these species have been found to be
immensely helpful in maintaining robust gut and immune health [55–57]. Further, a rise
in butyrogenic bacterial species Bifidobacterium following AG administration supports the
probiotic role of AG probably via increasing the butyrate levels in the gut and the systemic
circulation. The above increase in butyrate might also help in promoting anti-inflammatory
events by binding to GPR109A and triggering a robust Treg response [58]. On the other
hand, AG has been shown to be a strong inhibitor of NF-kB signaling thus blunting
proinflammatory pathways [59]. These roles depicted above might act in concert to amplify
the anti-inflammatory pathways thus attenuating DAMP release from the leaky gut.
One of the important mediators of proinflammatory pathways is the virome itself [60].
We have shown that the altered virome plays an integral role in the Gut–Brain-axis related
pathology in GWI [10]. AG administration not only restored the normal/healthy virome
but significantly created a distinct virome pattern where the classes of Myoviridae and
Siphoviridae were down-regulated, suggesting that the associated inflammatory pathways
triggered by the altered virome, e.g., increased systemic levels of IL-6 may be decreased
because of the virome-altering role of AG. Notably, an altered virome is also associated with
NAFLD and ulcerative colitis pathology [61,62]. AG effects on the virome and subsequent
proinflammatory pathways may be significantly effective in GI disturbances in general.
AG’s role in virome modulation is novel and is in addition to the anti-viral role of this
compound established in other studies [63]. GI disturbances and several other diseases
that are chronic in nature exhibit a leaky gut via the alteration of tight junction proteins,
namely, Occludin and Claudin-2 [64,65]. GWI has been found to harbor a leaky gut and a
decreased expression of Occludin with a concomitant rise in protein levels of Claudin-2 [6].
AG administration significantly restored the normal balance of these proteins suggesting
that it was effective in attenuating the leaky gut since there was a parallel decrease in IL-6
levels in the serum. Interestingly expression of either Claudin-2 or Occludinn is regulated
by a separate mode of proteins and small molecule intermediates endogenously found in
the intestinal epithelial cells. Vitamin D, transcription factors such as SNAIL and GRHL2
have been shown to be effectively modulating the expression of these proteins [35,66–68]. It
would be interesting to study the mechanisms of AG in controlling the transcription factors
both at the intestinal epithelium barrier and the BBB to know for certain the mechanisms
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involved in its effectiveness. In parallel, AG’s role in increasing the expression of bacteria
such as Akkermansia and Lachnospiraceae may also have a role in preserving the gut barrier
homeostasis since these bacteria have been shown to modulate the mucin layer in the
gastrointestinal epithelium [35]. A link between the bacterial metabolites such as butyrate
or others that can be released by Akkermansia may also induce transcriptional regulation of
barrier proteins via GRHL2/SNAIL, but that is hypothetical at this point.
AG was found to restore the virome diversity similar to healthy control mice in our
study. The virome families of Myoviridae and Siphoviridae often can have TLR7 as their
receptors for downstream signal modulations [69]. Our results of a mechanistic role of AG
in downregulating the TLR7 and its adaptor molecule MyD88 suggest that the AG’s role in
decreasing the abundance of Siphoviridae and Myoviridae may be playing a role in decreased
expression of these receptors. However, a parallel role of AG-induced transcriptional
regulation of both TLR7 and MyD88 cannot be ruled out especially when such regulations
are known by histone deacetylases [70]. Interestingly AG did not alter TLR4 protein levels
in the gut epithelia suggesting that the role of this broad-spectrum anti-viral may have a
direct effect on the TLR7 pathway.
A leaky gut resulting from the loss of barrier integrity in the intestine often results
in endotoxemia, activation of enteric glial cells, the release of nitric oxide, and localized
inflammation in the epithelial cells of the intestine [12,71]. The gut epithelia can then
secrete both IL-1β and IL-6, resulting in the significant increase of these proinflammatory
mediators in the systemic circulation [72]. AG significantly decreased these mediators
in the gut epithelia and in the systemic circulation, suggesting that the AG effect on the
virome, attenuation of TLR7 based downstream signaling, and its effect in attenuating
NF-kB might have resulted in decreased IL-1β and IL-6 protein levels in the epithelia and a
subsequent release of the mediators in the portal circulation. This pans well for a significant
decrease not only in the local milieu but also attenuates the parallel link to the brain since
gut proinflammatory mediators will most likely cross the BBB and result in inflammation
of the frontal cortex. AG-induced decrease in systemic levels of IL-1β and IL-6 is also proof
that our hypothesis of AG attenuation of epithelial cell inflammation is well versed given
that these cellular mediators can finally drain into the circulation.
Having established the role of AG in attenuating gastrointestinal inflammation, we
studied the effect of proinflammatory mediators and their likely effect on the BBB since
the barrier is a principal component of the Gut Brain-Axis. Our results of AG-induced
restoration of Claudin-5 expression in the brain endothelial cells in vivo suggest a significant role of AG in preserving this vital membrane integrity. Notably, we did not study the
leaky membrane at the BBB as this study, coupled with the estimation of Claudin-5 levels,
would have suggested that AG not only restored the protein levels of Claudin-5 but was
effective in functionally restoring it. A focused study involving AG’s role in BBB function
alone would definitely enhance the feasibility of the use of this natural compound in other
diseases that are linked to BBB dysfunction.
The BBB serves as a cohesive anatomical structure with defined functional roles that are
linked to several cell types such as pericytes, microglia, astrocytes, and the neuron [45,73].
It serves as the entry point of circulatory mediators both responsible for normal physiological functions and immune system regulation in the brain tissue. The endothelial cells of
the BBB have pronounced crosstalk with the above cell types and are often responsible for
maintaining homeostasis [73]. Microglia and astrocytes play an important role in immune
regulation, but many inflammatory phenotypes such as that seen in Alzheimer’s disease
(AD) or Parkinsonism result from proinflammatory actions of these cell types [74,75]. For
example, microglial activation may result in the release of proinflammatory cytokines
such as IL-1β, MCP-1 that in turn can activate the surrounding astrocytes for roles that
may perturb neurogenesis and synaptic plasticity [76,77]. GWI has been shown to affect
microglial action, astrocyte activation, more importantly, resulting in decreased BDNF
release, an important neurotrophic factor [11]. AG was found in our study to significantly
decrease microglial activation thus causing a decreased release of local IL-1β and IL-6 in
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the brain microenvironment. The above result is very significant and is relevant to the
attenuation of the proinflammatory signaling cascade that might have arisen because of the
ability of AG to block microglial activation. Furthermore, this result also might pave the
way for attenuating a decrease of BDNF release from the cells surrounding the microglia,
namely, the neurons in GW chemical exposed mice. To show that the crosstalk amongst the
various immune cell types, especially microglia and neurons, a mechanistic study needed
to be performed that would ensure that AG-induced mitigation of proinflammatory pathways in the brain runs through its actions on the microglia. We collected the microglial
secretome via harvesting the microglial conditioned medium (MCM) and subsequently
incubated it with the neuronal cells with this medium. Our results of AG attenuating
the phosphorylation of Tau, a clinical indicator of neurodegeneration and is clinically
associated with AD, proved that the natural broad-spectrum compound could not only
attenuate inflammation but could also decrease the accumulation of phosphorylated Tau
via microglial deactivation. Strikingly, GWI veterans have been found to have significantly
elevated levels of Tau antibodies that may have resulted from increased phosphorylation
of Tau though the mechanisms remain unclear [78]. Nevertheless, phosphorylated Tau remains a clinical biomarker of neurodegeneration and collapse of the cognitive trail [79–81].
AG-induced decrease of phosphorylated Tau via microglial deactivation might be an important pathway for its anti-inflammatory function in the brain microenvironment. The
decreased levels of apoptosis in the neuronal cells via the AG-treated microglia, induced
by a parallel IL-6 mediated pathway, also bears proof that AG is significantly attenuating
neuronal degeneration as a result of inflammation.
In summary, we report a novel role of AG in regulating the Gut–Brain-Axis pathology
in a mouse model of GWI. Though on a smaller scale, the in vivo result in this murine
model definitely adds to a novel body of evidence that is specific to the broad-spectrum
role of a natural compound that has been used in countries such as India and China for
ages. This also bodes very well for a single drug approach to treat a plethora of chronic
multisymptomatic illnesses such as chronic fatigue syndrome, fibromyalgia in addition to
GWI. As we learn more about the role of the Gut–Brain Axis in the pathology of diseases,
natural compounds with such broad-spectrum roles might be needed to mitigate the
chronicity of the diseases mentioned above. Moreover, the usefulness of a drug that has
very few side effects combined with a history of being used for generations may well fit
for the quick bench to bedside strategies. However, more mechanistic studies need to be
carried out in each component of the Gut–Brain Axis compartment to ensure the specific
yet novel roles of this compound. Further, additional studies in a symptom persistence
model that truly reflects the health state of the GW veteran need to be performed to show
the therapeutic effect of andrographolide.
5. Conclusions
As supported by both in vivo and in vivo evidence obtained from the current study,
the phytochemical andrographolide proved to be a potent therapeutic candidate for
GWI-associated pathology and can be further examined by clinical trials to treat the
GWI veterans.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/brainsci11070905/s1, Figure S1. (A) PCoA plot of viral Bray–Curtis distances colored by
Occludin level (PERMANOVA p = 0.041). (B) PcoA plot of viral Bray–Curtis distances colored by
Claudin-2 level (PERMANOVA p = 0.19). (C) PCoA plot of viral Bray–Curtis distances colored
by IL-6 level (PERMANOVA p = 0.17). (D) PCoA plot of viral Bray–Curtis distances colored by
Claudin-5 and CD31 levels (PERMANOVA p = 0.35), Figure S2. Decontam relative abundance of
virome family collected from fecal pellets. Relative abundance of samples colored by decontam
contaminant classification at a prevalence threshold of 0.3. Red indicates sample-specific values that
were retained for analysis. Blue indicates values classified as contaminants that were removed, Table
S1. Viral taxonomy of all contigs used in the study. Taxonomy retrieved from BLAST accession IDs
using taxonomizr, Table S2. Viral features identified by LEfSe as discriminant by treatment group.
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Pairwise comparisons between treatment groups are shown in each tab, Table S3. Significant results
were identified by MaAsLin2 for Occludin, IL-6, Claudin-2, and Claudin-5, and CD31 levels.
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